Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘Prostate Cancer Market Opportunity’

Zytiga European Prostate Cancer approval may kill Jevtana sales

By on August 4, 2011

With the collapse of the Dendreon share price today following poor sales data (Adam Feuerstein on The Street has an excellent write up about this), attention has again focused on the prostate cancer market.

Zytiga (abiraterone acetate) was recently approved by the European Medicines Agency (EMA), following FDA approval earlier this year.

The EMA Committee for Medicinal Products for Human Use granted the marketing authorization for Zytiga at it’s July 2011 meeting.  The approval noted,

“The poor prognosis of the target patient population represents a high unmet medical need while the novel mechanism of action of abiraterone has the potential to offer an alternative therapeutic option for these patients.”

This is a preview of Zytiga European Prostate Cancer approval may kill Jevtana sales. Read the full post

Leave a comment

Prostate Cancer Market to expand from $1B to $5B by 2015

By on June 2, 2011

Launch of Zytiga at AUA 2011 300x225 Prostate Cancer Market to expand from $1B to $5B by 2015The market for prostate cancer therapies is set to expand from $1 billion currently to $5 billion by 2015, according to analysts reported by this morning’s Washington Post/Bloomberg news.  This is perhaps no surprise given the recent approval of abiraterone acetate (Zytiga®) from Ortho Biotech (JNJ).

New clinical data on prostate cancer clinical trial results is expected at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago this weekend from many of the prostate cancer therapies in development such as MDV3100, TAK700, ARN-509, cabozantinib (XL184), ipilimumab, custirsen (OGX-11), BPX-101, alpharadin, denosumab (Xgeva®) and Prostvac-VF.

This is a preview of Prostate Cancer Market to expand from $1B to $5B by 2015. Read the full post

Leave a comment

AUA 2011 New Prostate Cancer products in development beyond the androgen axis

By on May 16, 2011

AUA 2011 Washington DC © Pieter Droppert 300x225 AUA 2011 New Prostate Cancer products in development beyond the androgen axisThere is a lot of focus at the annual meeting of the American Urological Association (AUA) here in Washington DC on metastatic castrate resistant Prostate Cancer (mCRPC), and the recently FDA approved adrenal steroid inhibitor, abiraterone acetate (Zytiga®).

Drugs in development that target the androgen receptor, such as MDV3100, are also generating a lot of interest from urologists.

However, Oliver Sartor (Tulane) in the Saturday morning satellite symposia that I attended, focused on emerging therapies in CRPC, beyond the androgen axis. His hypothesis:

“Cancers are devious and some of the mechanisms of AR activation appear to be ligand-independent and resistant to all current androgen-axis targeted therapies.”

This is a preview of AUA 2011 New Prostate Cancer products in development beyond the androgen axis. Read the full post

1 Comment